Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 w » 5 wt (Expand Search)
Showing 141 - 160 results of 100,701 for search '(( 5 w decrease ) OR ( 5 ((fold decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.52s Refine Results
  1. 141
    Decrease of mitochondrial protein levels in human OPMD muscle biopsies.

    Decrease of mitochondrial protein levels in human OPMD muscle biopsies. by Aymeric Chartier (713911)

    Published 2015
    Save to List
    Saved in:
  2. 142
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 143
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 144
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 145
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 146
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 147
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 148
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 149
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 150
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 151
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 152
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 153
    Six weeks of voluntary wheel running decreases 5-HT<sub>2C</sub> mRNA expression in the medial dorsal striatum.

    Six weeks of voluntary wheel running decreases 5-HT<sub>2C</sub> mRNA expression in the medial dorsal striatum. by Benjamin N. Greenwood (295216)

    Published 2013
    Save to List
    Saved in:
  14. 154
    CK2α decreases CLK transcription factor activity.

    CK2α decreases CLK transcription factor activity. by Áron Szabó (450885)

    Published 2013
    Save to List
    Saved in:
  15. 155
    Overexpression of Lethe in RAW macrophage cells decreases ROS production.

    Overexpression of Lethe in RAW macrophage cells decreases ROS production. by Carlos Zgheib (311460)

    Published 2017
    Save to List
    Saved in:
  16. 156
    CMV infection decreases TER of polarized HCoEpiC.

    CMV infection decreases TER of polarized HCoEpiC. by Ekaterina Maidji (3797899)

    Published 2017
    Save to List
    Saved in:
  17. 157
    Treatment with anti-JAM-C antibody decreases the T-cell response

    Treatment with anti-JAM-C antibody decreases the T-cell response by Gaby Palmer (636)

    Published 2011
    Save to List
    Saved in:
  18. 158
    Decreasing bioavailable copper in vivo modulates tumor vessel dimensions.

    Decreasing bioavailable copper in vivo modulates tumor vessel dimensions. by Andrew Crowe (450839)

    Published 2013
    Save to List
    Saved in:
  19. 159
    mTOR activity is decreased in KSR1-deficient T cells.

    mTOR activity is decreased in KSR1-deficient T cells. by Marie Le Borgne (337225)

    Published 2013
    Save to List
    Saved in:
  20. 160
    Processive receptor methylation compromises adaptation and decreases signaling noise.

    Processive receptor methylation compromises adaptation and decreases signaling noise. by William Pontius (460803)

    Published 2013
    “…(C) Increasing processivity also decreases the magnitude of fluctuations in <i>a</i>(<i>t</i>) in the adapted state around the mean value <i>a</i><sub>0</sub>. …”
    Save to List
    Saved in:

Search Tools: